Current stock page

Stock Analysis

Phreesia, Inc. (PHR) Stock Analysis

Phreesia, Inc. (PHR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PHR Stock Analysis Summary

Phreesia, Inc. (PHR) currently has an AIQ Score of 44/100, indicating a neutral setup. Quality is the strongest factor at 59/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 11, 2026 · Market-close data

PHR at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$10.31
AIQ Score44/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$731.85M
P/E Ratio42.29
Forward P/E
EPS$0.03
Revenue TTM$129.46M
Dividend Yield0.00%
Beta0.84
Volume526.88K
52-week range$7.77-$27.00
RSI 1425.74
50-Day SMA$11.23
200-Day SMA$12.11
Analyst Price Target$11.89
Next EarningsDec 14, 2026
As of Sep 11, 2026 · Market close
Free research limit

Create a free account to keep researching stocks

You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.

PHR

Overview
Phreesia, Inc.
Healthcare· Medical - Healthcare Information Services
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 11, 2026
Last price
$10.31
+$0.14 (+1.38%)
Latest market quote
Momentum24
Value42
Quality59
Risk Resilience50
Sentiment50
View financial data

PHR Stock Analysis Summary

Phreesia, Inc. (PHR) currently has an AIQ Score of 44/100, indicating a neutral setup. Quality is the strongest factor at 59/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 11, 2026 · Market-close data
AIQ Composite Posture: Mixed

In a neutral regime, PHR has AIQ Score of 44/100 with Quality base of 59/100 and fading Momentum at 24/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (59/100) leads while Momentum (24/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.38% stock move · PHR classified in Medical - Healthcare Information Services.

Current Evidence

NeutralPHR is in a neutral AIQ regime; Quality is the strongest visible factor at 59/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PHR Bullish or Bearish Right Now?

PHR currently has a neutral overall setup. Quality is the strongest factor at 59/100, while Momentum is weakest at 24/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +15.32% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 42/100.
  • - Momentum is weak at 24/100.
  • - Price is -14.87% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 7).

Current Consensus

PHR's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 1 neutral, and 37 sell votes. PHR's 14-day RSI is 25.74, which places the stock in an oversold momentum range. PHR's beta is 0.84, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in PHR?

Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.

AIQ Score
44/100
Momentum
24/100
Quality
59/100
Risk
50/100

What Would Change the PHR Outlook?

The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PHR Decision Framework

Public evidence layers, setup checks, and risk context for Phreesia, Inc..

Phreesia, Inc. (PHR) Stock Analysis

Phreesia, Inc. has an AIQ Score of 44/100 in a Neutral regime. Quality is strongest at 59/100. Beta is 0.84, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPHR is in a Neutral AIQ regime with score 44/100.
Signal ConflictThe primary conflict is that quality leads at 59/100 while momentum lags at 24/100.
Factor EvidenceMomentum 24/100 · Value 42/100 · Quality 59/100 · Risk 50/100 · Sentiment 50/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Quality is the strongest factor at 59/100.

TimingFail

Momentum is 24/100 and RSI (14) is 25.7.

Regime fitWait

PHR is in a Neutral regime at 44/100.

Risk controlWait

Risk factor is 50/100 with beta 0.84 and annual volatility 58.56%.

ConflictWait

Current conflict: quality leads at 59/100 while momentum lags at 24/100.

AIQ Score
44/100
Price
$10.31
Beta
0.84
RSI (14)
25.7

PHR Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PHR Fundamentals

PHR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$129.46M
Net income
$4.56M
Free cash flow
$17.84M
View full PHR fundamental analysis

PHR Technical Analysis

PHR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
25.74
Price vs SMA-50
-8.20%
View full PHR technical analysis

PHR Stock Catalysts

Track PHR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Dec 14, 2026
Analyst target
$11.89
News items
5
View PHR earnings and stock catalysts

PHR Dividend Analysis

PHR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
Payout ratio
View PHR dividend history and analysis

PHR Financial Data

PHR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$129.46M
EPS
$0.03
Periods
8
View PHR financials

PHR Risk Analysis

PHR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.84
Risk score
50/100
1Y volatility
58.56%
View PHR risk analysis

PHR Stock News

PHR stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Sep 11, 2026
Sentiment
50/100
Read PHR stock news

PHR vs Healthcare Services / Managed Care Peers

Current peer cohort: PHR · PRVA · TDOC · UHS · UNH. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PHR
Current stock
44/10042/10024/10050/100-1.2958.56%Current
PRVA
Privia Health
40/10042/10026/10072/100-0.331.88%PHR vs PRVA
TDOC
Teladoc Health
47/10065/10035/10027/100-0.0364.39%PHR vs TDOC
UHS
Universal Health Services
64/10073/10050/10060/100-0.1532.33%PHR vs UHS
UNH
UnitedHealth Group
50/10059/10040/10058/1000.3234.65%PHR vs UNH
Pairwise Compare links: PRVA · TDOC · UHS · UNHPHR vs PRVAPHR vs TDOCPHR vs UHSPHR vs UNHCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Sep 11, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PHR stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Sep 12, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
77.79
As of Sep 11, 2026
Revenue growth
3.04%
Gross margin
65.81%
Current debt / equity
0.26
Latest quarterly evidence

Latest period Jul 31, 2026.

Review fundamentals
Quarter revenue
$129.46M
Quarter net income
$4.56M
Quarter free cash flow
$17.84M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
25.74
MACD
-0.26

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
50/100
Beta
0.84
Annual volatility
58.56%
Max drawdown
-68.37%

PHR Stock FAQ

What is PHR stock price today?

Phreesia, Inc.'s current stock price is $10.31. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PHR bullish or bearish right now?

PHR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PHR's market cap?

PHR's market cap is $731.85M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PHR's current P/E ratio?

PHR's current P/E ratio is 42.29 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PHR's RSI?

PHR's 14-day RSI is 25.74 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PHR above its 50-day and 200-day moving averages?

PHR is -8.20% from its 50-day SMA and -14.87% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PHR's next earnings date?

PHR's next earnings date is currently listed as Dec 14, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PHR pay a dividend?

PHR's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.